Mesenchymal Stromal Cell-Based Therapy: A Promising Approach for Severe COVID-19

Mesenchymal Stromal Cell-Based Therapy: A Promising Approach for Severe COVID-19

During the outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), many critically ill patients died of severe pneumonia, acute respiratory distress syndrome (ARDS), or multiple organ dysfunction syndrome. To date, no specific treatments have been proven to be effective for coronav...

Full description

Bibliographic Details
Main Authors: Jing Xiong, Long Chen, Li Zhang, Lei Bao, Yuan Shi
Format: Article
Language:English
Published: SAGE Publishing 2021-03-01
Series:Cell Transplantation
Online Access:https://doi.org/10.1177/0963689721995455
id doaj-9c67b89899ff4e859ab1e524e1ee2d3d
record_format Article
spelling doaj-9c67b89899ff4e859ab1e524e1ee2d3d2021-03-02T23:33:33ZengSAGE PublishingCell Transplantation1555-38922021-03-013010.1177/0963689721995455Mesenchymal Stromal Cell-Based Therapy: A Promising Approach for Severe COVID-19Jing Xiong0Long Chen1Li Zhang2Lei Bao3Yuan Shi4 Department of Neonatology, Children’s Hospital of Chongqing Medical University, Chongqing, China  Department of Neonatology, Children’s Hospital of Chongqing Medical University, Chongqing, China  Department of Pulmonology, Children’s Hospital of Chongqing Medical University, Chongqing, China Department of Neonatology, Children’s Hospital of Chongqing Medical University, Chongqing, China  Department of Neonatology, Children’s Hospital of Chongqing Medical University, Chongqing, China During the outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), many critically ill patients died of severe pneumonia, acute respiratory distress syndrome (ARDS), or multiple organ dysfunction syndrome. To date, no specific treatments have been proven to be effective for coronavirus disease 2019 (COVID-19). In the animal models and clinical applications, mesenchymal stromal/stem cells (MSCs) have been shown safety and efficacy for the treatment of respiratory virus infection through their abilities of differentiation and immunomodulation. Besides, possessing several advantages of MSC-derived extracellular vesicles (EVs) over MSCs, EV-based therapy also holds potential therapeutic effects in respiratory virus infection. In this review, we summarized the basic characteristics and mechanisms of COVID-19 and MSCs, outlined some preclinical and clinical studies of MSCs or MSC-EVs for respiratory virus infection such as influenza virus and SARS-CoV-2, shed light on the common problems that we should overcome to translate MSC therapy into clinical application, and discussed some safe issues related to the use of MSCs.https://doi.org/10.1177/0963689721995455
collection DOAJ
language English
format Article
sources DOAJ
author Jing Xiong
Long Chen
Li Zhang
Lei Bao
Yuan Shi
spellingShingle Jing Xiong
Long Chen
Li Zhang
Lei Bao
Yuan Shi
Mesenchymal Stromal Cell-Based Therapy: A Promising Approach for Severe COVID-19
Cell Transplantation
author_facet Jing Xiong
Long Chen
Li Zhang
Lei Bao
Yuan Shi
author_sort Jing Xiong
title Mesenchymal Stromal Cell-Based Therapy: A Promising Approach for Severe COVID-19
title_short Mesenchymal Stromal Cell-Based Therapy: A Promising Approach for Severe COVID-19
title_full Mesenchymal Stromal Cell-Based Therapy: A Promising Approach for Severe COVID-19
title_fullStr Mesenchymal Stromal Cell-Based Therapy: A Promising Approach for Severe COVID-19
title_full_unstemmed Mesenchymal Stromal Cell-Based Therapy: A Promising Approach for Severe COVID-19
title_sort mesenchymal stromal cell-based therapy: a promising approach for severe covid-19
publisher SAGE Publishing
series Cell Transplantation
issn 1555-3892
publishDate 2021-03-01
description During the outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), many critically ill patients died of severe pneumonia, acute respiratory distress syndrome (ARDS), or multiple organ dysfunction syndrome. To date, no specific treatments have been proven to be effective for coronavirus disease 2019 (COVID-19). In the animal models and clinical applications, mesenchymal stromal/stem cells (MSCs) have been shown safety and efficacy for the treatment of respiratory virus infection through their abilities of differentiation and immunomodulation. Besides, possessing several advantages of MSC-derived extracellular vesicles (EVs) over MSCs, EV-based therapy also holds potential therapeutic effects in respiratory virus infection. In this review, we summarized the basic characteristics and mechanisms of COVID-19 and MSCs, outlined some preclinical and clinical studies of MSCs or MSC-EVs for respiratory virus infection such as influenza virus and SARS-CoV-2, shed light on the common problems that we should overcome to translate MSC therapy into clinical application, and discussed some safe issues related to the use of MSCs.
url https://doi.org/10.1177/0963689721995455
work_keys_str_mv AT jingxiong mesenchymalstromalcellbasedtherapyapromisingapproachforseverecovid19
AT longchen mesenchymalstromalcellbasedtherapyapromisingapproachforseverecovid19
AT lizhang mesenchymalstromalcellbasedtherapyapromisingapproachforseverecovid19
AT leibao mesenchymalstromalcellbasedtherapyapromisingapproachforseverecovid19
AT yuanshi mesenchymalstromalcellbasedtherapyapromisingapproachforseverecovid19
_version_ 1724234048759398400

Similar Items